Lock up all RGBP shares with GTC sell orders at dollars and soon we should be in dimes and quarters. Watch for filings to begin dropping also along with news next week!
All Lilly did was allow Regen access to their molecule library to test molecules against the NR2F6 receptor. Speculation was that Lilly, assuming Regen was successful, would end up licensing the patent. A ex Lilly exec even briefly joined Regen's board.